Yahoo Finance2d
60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Sixty Degrees Pharmaceuticals Thu, Jan 30, 2025, 2:20 PM 6 min read ...
Yahoo Finance5d
60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis
Enrollment expected to commence Q3 2025. WASHINGTON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused ...
Nasdaq5d
60 Degrees Pharmaceuticals, Inc. Receives IRB Approval for Phase II Clinical Study of Tafenoquine in Chronic Babesiosis Treatment
60 Degrees Pharmaceuticals, Inc. announced the approval of an Investigational Review Board (IRB) for a Phase II clinical study aimed at evaluating the efficacy and safety of tafenoquine ...
Yahoo Finance3d
60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
WASHINGTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious ...
Yahoo Finance5d
60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis
Enrollment expected to commence Q3 2025. WASHINGTON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on ...
clinicaltrialsarena4d
60 Degrees Pharmaceuticals obtains IRB approval for chronic babesiosis therapy trial
Babesiosis is a tick-borne illness caused by babesia parasites. Credit: Yuriy K / Shutterstock. US-based pharmaceutical company 60 Degrees Pharmaceuticals has received approval from the ...